文献速递消化道肿瘤放疗

新辅助SBRT联合选择性淋巴结照射同步卡培他滨治疗可切除胰腺癌的生存分析

Neoadjuvant Stereotactic Body Radiation Therapy Plus Elective Nodal Irradiation With Concurrent Capecitabine for Patients With Resectable Pancreatic Cancer: Survival Analysis of a Prospective Phase 1 Trial.
PubMed 文献 · Pract Radiat Oncol · 2025-02-07

这项前瞻性单中心1A/B期剂量递增试验纳入2014至2019年活检证实的可切除胰腺腺癌患者,原发灶接受5次5、6或7 Gy新辅助SBRT同步卡培他滨(1650 mg/m2),所有患者接受选择性淋巴结照射(5 Gy×5次)。17例入组、16例可评估,13例(76.5%)接受手术;中位随访28.0个月,中位OS和DFS分别为31.1个月和12.0个月,病理淋巴结阳性与更高的复发和远处转移风险相关。作者认为该方案可行,可能改善可切除及交界可切除胰腺癌患者的结局,并需在更大队列中进一步研究。

要点

  • 16例可评估患者中13例(76.5%)接受手术,中位OS为31.1个月,中位DFS为12.0个月。
  • 病理淋巴结阳性(69.2%)与任何复发风险升高(P<.01)和远处转移风险升高(P=.02)相关。
  • 淋巴结阳性患者中位OS为23.9个月 vs 淋巴结阴性69.3个月(P=.002),中位DFS为9.9个月 vs 58.9个月(P=.002)。

核心结论

  • 作者认为,原发灶新辅助SBRT联合选择性淋巴结照射及放疗增敏化疗是一种可行的方法,可能改善可切除及交界可切除胰腺癌患者的结局,尽管病理淋巴结受累率较高。
  • 作者认为该策略需在更大队列中进一步研究。

研究设计与样本

  • 前瞻性单中心1A/B期剂量递增试验,2014至2019年纳入活检证实的可切除胰腺腺癌患者(NCT1918644)。
  • 患者进入3个递增剂量队列之一,原发灶新辅助SBRT为5次5、6或7 Gy,同步卡培他滨1650 mg/m2。
  • 所有患者接受选择性淋巴结照射5 Gy×5次。
  • 17例入组,16例可评估(94.1%)。

主要发现

  • 13例(76.5%)接受手术,4例(25.0%)接受新辅助化疗,6例(37.5%)接受辅助化疗。
  • 中位随访28.0个月(范围1.7-71.9个月),中位OS为31.1个月(范围2.3-73.6个月),中位DFS为12.0个月(范围0.4-71.9个月)。
  • 3年OS和DFS总体分别为50%和31.3%,手术队列分别为61.5%和38.5%。
  • 局部失败4例(25%),其中2例部分位于25 Gy选择性淋巴结野内,1例位于25 Gy选择性淋巴结野内并部分位于35 Gy肿瘤野内。
  • 淋巴结阳性患者中位OS为23.9个月 vs 淋巴结阴性69.3个月(P=.002),中位DFS为9.9个月 vs 58.9个月(P=.002)。

关键数值与推荐

  • 病理淋巴结受累(69.2%)与任何复发风险升高相关(P<.01),与远处转移风险升高相关(P=.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为该策略需在更大队列中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Elective nodal irradiation (ENI) in resectable pancreatic cancer remains undefined, although occult nodal disease is common. This study investigated the use of neoadjuvant stereotactic body radiation therapy (SBRT) for primary disease with ENI, with concurrent capecitabine therapy. Safety data for this protocol were previously reported. In this report, we provided an updated survival analysis. METHODS AND MATERIALS: This is a prospective, single institution, phase 1A/B dose-escalation trial that enrolled patients with biopsy-proven, resectable, pancreatic adenocarcinoma between 2014 and 2019 (NCT1918644). Patients were enrolled into 1 of the 3 cohorts with escalating dose levels. Neoadjuvant SBRT to the primary tumor was delivered in 5 fractions of 5, 6, or 7 Gy with concomitant capecitabine (1650 mg/m2). All patients received ENI (5 Gy × 5 fractions). Our initial report found no dose-limiting toxicities. Clinicopathologic features were summarized using descriptive statistics. Kaplan-Meier curves were employed for survival analysis. RESULTS: Of 17 enrolled patients, 16 were evaluable (94.1%). Thirteen (76.5%) proceeded to surgery. The median follow-up was 28.0 (range, 1.7-71.9) months. Four patients (25.0%) received neoadjuvant chemotherapy, and 6 (37.5%) received adjuvant chemotherapy. Pathologic nodal involvement (69.2%) was associated with a higher risk of any relapse (P < .01) and distant metastasis (P = .02). Local failure occurred in 4 (25%) patients, with 2 of 4 of those failures occurring partially within the 25 Gy elective nodal field and 1 of 4 occurring in the 25 Gy elective nodal field and partially within the 35 Gy tumor field. The median overall survival (OS) and disease-free survival (DFS) were 31.1 (range, 2.3-73.6) months and 12.0 (range, 0.4-71.9) months, respectively. Three-year OS and DFS were 50% and 31.3% overall, and 61.5% and 38.5% for the surgical cohort. Patients with positive lymph nodes had worse median OS (23.9 vs 69.3 months; P = .002) and DFS (9.9 vs 58.9 months; P = .002). No further radiation-related toxicities were noted since the prior report. CONCLUSIONS: Neoadjuvant SBRT to the primary tumor with ENI and radiosensitizing chemotherapy is a feasible approach that may improve outcomes in patients with resectable and borderline pancreatic cancer, despite high rates of pathologic nodal involvement. Further investigation of this strategy is warranted in a larger cohort.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Basree MM, Witt JS, Uboha NV, et al. Neoadjuvant Stereotactic Body Radiation Therapy Plus Elective Nodal Irradiation With Concurrent Capecitabine for Patients With Resectable Pancreatic Cancer: Survival Analysis of a Prospective Phase 1 Trial. Pract Radiat Oncol. 2025. PMID: 39924052. doi:10.1016/j.prro.2025.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。